C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Historical Holders from Q4 2020 to Q3 2025

Symbol
CCCC on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
71.4M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
52.5M
Holdings value
$117M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
96
Number of buys
47
Number of sells
-63
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $50.3M 22.6M Point72 Asset Management, L.P. 17 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $21M $21M 9.44M RA Capital Management, L.P. 17 Oct 2025
Bain Capital Life Sciences Fund II, L.P. 6.25% $13.5M 6.06M BCLS II Equity Opportunities, LP 17 Oct 2025
WASATCH ADVISORS LP 6.8% -33.6% $10.8M -$5.82M 4.85M -35.1% Wasatch Advisors LP 30 Sep 2025
MORGAN STANLEY 6.7% +26% $7.03M $1.36M 4.75M +24.1% Morgan Stanley 30 Jun 2025
ORBIMED ADVISORS LLC 5% -22.9% $7.92M -$2.41M 3.57M -23.4% OrbiMed Capital LLC 30 Sep 2025
BlackRock, Inc. 2.5% $2.51M 1.76M BlackRock, Inc. 30 Jun 2025

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 52.5M $117M -$3.49M $2.22 96
2025 Q2 54.7M $78.2M -$14.7M $1.43 102
2025 Q1 64.1M $103M -$12.6M $1.60 113
2024 Q4 64.4M $232M -$9.81M $3.60 113
2024 Q3 64.2M $366M +$21.1M $5.70 118
2024 Q2 60.9M $281M +$5.55M $4.62 114
2024 Q1 58.2M $476M +$93.9M $8.17 104
2023 Q4 47M $266M +$85.4M $5.65 91
2023 Q3 34.7M $64.5M -$134K $1.86 82
2023 Q2 34.2M $94.1M -$9.38M $2.75 96
2023 Q1 37.4M $117M -$15.2M $3.14 117
2022 Q4 39.2M $231M -$9.77M $5.90 113
2022 Q3 39.5M $346M -$2.52M $8.77 115
2022 Q2 39.4M $297M -$40M $7.54 111
2022 Q1 37.3M $905M +$6.53M $24.26 120
2021 Q4 35.9M $1.15B +$16.7M $32.20 115
2021 Q3 34.5M $1.54B +$111M $44.68 110
2021 Q2 31.9M $1.21B +$260M $37.84 106
2021 Q1 25.1M $927M +$90.4M $36.99 83
2020 Q4 22.7M $744M +$719M $33.13 75